The European Commission has officially granted marketing authorization for Gotenfia, a golimumab biosimilar developed through the partnership between Bio-Thera and STADA.
Key Highlights
-
Reference Product: Gotenfia was developed as a biosimilar version of the original biologic drug, Simponi.
-
Partnership Roles: While Bio-Thera led the technical development and manufacturing, STADA will manage the commercialization and marketing activities across Europe.
-
Impact: This regulatory clearance provides healthcare systems in the EU with a more cost-effective alternative for treating autoimmune conditions, enhancing patient access to essential therapies.